496.95
0.56%
-2.82
Idexx Laboratories, Inc. stock is currently priced at $496.95, with a 24-hour trading volume of 883.85K.
It has seen a -0.56% decreased in the last 24 hours and a +0.85% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $498.9 pivot point. If it approaches the $495.9 support level, significant changes may occur.
Previous Close:
$499.77
Open:
$500.17
24h Volume:
883.85K
Market Cap:
$41.04B
Revenue:
$3.72B
Net Income/Loss:
$866.57M
P/E Ratio:
50.71
EPS:
9.8
Net Cash Flow:
$796.79M
1W Performance:
-3.79%
1M Performance:
+0.85%
6M Performance:
+6.68%
1Y Performance:
+6.92%
Idexx Laboratories, Inc. Stock (IDXX) Company Profile
Name
Idexx Laboratories, Inc.
Sector
Industry
Phone
207-556-0300
Address
One IDEXX Drive, Westbrook, ME
Idexx Laboratories, Inc. Stock (IDXX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
Jul-25-22 | Downgrade | Stifel | Buy → Hold |
Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
Jul-12-22 | Initiated | Piper Sandler | Overweight |
May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
Feb-08-22 | Initiated | Atlantic Equities | Overweight |
Nov-18-21 | Initiated | Morgan Stanley | Overweight |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
Feb-17-21 | Initiated | Barclays | Overweight |
Sep-09-19 | Initiated | Goldman | Neutral |
May-23-19 | Initiated | Guggenheim | Buy |
Nov-02-18 | Reiterated | BofA/Merrill | Buy |
May-07-18 | Reiterated | Stifel | Buy |
Jan-16-18 | Initiated | Piper Jaffray | Overweight |
Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Jul-28-17 | Upgrade | CL King | Neutral → Buy |
Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
Sep-29-16 | Resumed | BofA/Merrill | Neutral |
Aug-16-16 | Reiterated | Stifel | Buy |
Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
Apr-01-16 | Initiated | CL King | Neutral |
Mar-21-16 | Reiterated | Stifel | Buy |
Feb-04-16 | Initiated | Credit Suisse | Outperform |
Oct-29-15 | Reiterated | Stifel | Buy |
Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-13-15 | Reiterated | Stifel | Buy |
Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories, Inc. Stock (IDXX) Latest News
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
MarketWatch
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Cambridge Investment Research Advisors Inc. - Defense World
Defense World
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report? - Yahoo Finance
Yahoo Finance
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? - Yahoo News UK
Yahoo News UK
Roundview Capital LLC Acquires Shares of 3,184 IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
MarketBeat
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
MarketWatch
Idexx Laboratories, Inc. Stock (IDXX) Financials Data
Idexx Laboratories, Inc. (IDXX) Revenue 2024
IDXX reported a revenue (TTM) of $3.72 billion for the quarter ending March 31, 2024, a +8.57% rise year-over-year.
Idexx Laboratories, Inc. (IDXX) Net Income 2024
IDXX net income (TTM) was $866.57 million for the quarter ending March 31, 2024, a +23.94% increase year-over-year.
Idexx Laboratories, Inc. (IDXX) Cash Flow 2024
IDXX recorded a free cash flow (TTM) of $796.79 million for the quarter ending March 31, 2024, a +74.86% increase year-over-year.
Idexx Laboratories, Inc. (IDXX) Earnings per Share 2024
IDXX earnings per share (TTM) was $10.33 for the quarter ending March 31, 2024, a +24.31% growth year-over-year.
Idexx Laboratories, Inc. Stock (IDXX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Claflin Bruce L. | Director |
May 17 '24 |
Sale |
540.80 |
200 |
108,160 |
161 |
Kingsley Lawrence D | Director |
May 06 '24 |
Option Exercise |
0.00 |
339 |
0 |
8,883 |
SZOSTAK M ANNE | Director |
May 06 '24 |
Option Exercise |
0.00 |
257 |
0 |
257 |
Vandebroek Sophie V. | Director |
May 06 '24 |
Option Exercise |
0.00 |
257 |
0 |
1,473 |
COLLINS Asha | Director |
May 06 '24 |
Option Exercise |
0.00 |
257 |
0 |
779 |
ESSIG STUART | Director |
May 06 '24 |
Option Exercise |
0.00 |
257 |
0 |
1,974 |
AYERS JONATHAN W | Director |
May 06 '24 |
Option Exercise |
0.00 |
257 |
0 |
265,651 |
Britt Irene Chang | Director |
May 06 '24 |
Option Exercise |
0.00 |
208 |
0 |
208 |
POLEWACZYK JAMES F | Executive Vice President |
Mar 06 '24 |
Option Exercise |
422.45 |
8,104 |
3,423,547 |
18,815 |
POLEWACZYK JAMES F | Executive Vice President |
Mar 06 '24 |
Sale |
558.44 |
8,104 |
4,525,596 |
10,711 |
About Idexx Laboratories, Inc.
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Cap:
|
Volume (24h):